2-Hydroxypropyl-beta-cyclodextrin clinical trials
How each study uses 2-Hydroxypropyl-beta-cyclodextrin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2017 | 2 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Cyclo Therapeutics, Inc. (5)
Studies
Open first, then newest update. How each study uses 2-Hydroxypropyl-beta-cyclodextrin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1Active, not recruitingPhase 3Cyclo Therapeutics, Inc.NCT04860960Written as Hydroxypropyl-beta-cyclodextrin
- A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's DiseaseStatus unknownPhase 2Cyclo Therapeutics, Inc.NCT05607615Written as Hydroxypropyl Beta Cyclodextrin
- Safety and Efficacy of Intravenous Trappsol Cyclo (HPBCD) in Niemann-Pick Type C PatientsCompletedPhase 1/2Cyclo Therapeutics, Inc.NCT02912793Written as Hydroxypropyl-beta-cyclodextrin
- Open-Label Study of Long-Term Safety and Efficacy of Intravenous Trappsol Cyclo (HPβCD) in Niemann-Pick Disease Type CStatus unknownPhase 1Cyclo Therapeutics, Inc.NCT03893071Written as Hydroxypropyl-β-cyclodextrin
- Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1)CompletedPhase 1Cyclo Therapeutics, Inc.NCT02939547Written as Hydroxypropyl-beta-cyclodextrin
Codes
What other systems call 2-Hydroxypropyl-beta-cyclodextrin · ClinicalTrials.gg INT006627
- MeSH (NLM) D0000737382-Hydroxypropyl-beta-cyclodextrinConfirmed NLM, Wikidata
- UNII (FDA) 1I96OHX6EKHYDROXYPROPYL BETADEXConfirmed NLM, Wikidata
- RxNorm 1363608One source FDA
- Wikidata Q72481481Hydroxypropyl-beta-cyclodextrinConfirmed NLM, Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000073738 | 2-Hydroxypropyl-beta-cyclodextrin | Confirmed NLM, Wikidata |
| UNII (FDA) | 1I96OHX6EK | HYDROXYPROPYL BETADEX | Confirmed NLM, Wikidata |
| RxNorm | 1363608 | — | One source FDA |
| Wikidata | Q72481481 | Hydroxypropyl-beta-cyclodextrin | Confirmed NLM, Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.